Logo image of ICCM

ICECURE MEDICAL LTD (ICCM) Stock Fundamental Analysis

USA - NASDAQ:ICCM - IL0011224156 - Common Stock

1.04 USD
+0.02 (+1.96%)
Last: 9/18/2025, 8:00:01 PM
1.03 USD
-0.01 (-0.96%)
After Hours: 9/18/2025, 8:00:01 PM
Fundamental Rating

2

Overall ICCM gets a fundamental rating of 2 out of 10. We evaluated ICCM against 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ICCM have multiple concerns. ICCM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ICCM has reported negative net income.
In the past year ICCM has reported a negative cash flow from operations.
ICCM had negative earnings in each of the past 5 years.
ICCM had a negative operating cash flow in each of the past 5 years.
ICCM Yearly Net Income VS EBIT VS OCF VS FCFICCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

ICCM's Return On Assets of -147.13% is on the low side compared to the rest of the industry. ICCM is outperformed by 86.91% of its industry peers.
ICCM has a worse Return On Equity (-538.91%) than 85.86% of its industry peers.
Industry RankSector Rank
ROA -147.13%
ROE -538.91%
ROIC N/A
ROA(3y)-89.11%
ROA(5y)-66.89%
ROE(3y)-136.41%
ROE(5y)-102.39%
ROIC(3y)N/A
ROIC(5y)N/A
ICCM Yearly ROA, ROE, ROICICCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

ICCM's Gross Margin of 35.92% is on the low side compared to the rest of the industry. ICCM is outperformed by 71.20% of its industry peers.
ICCM's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ICCM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.03%
GM growth 5Y4.86%
ICCM Yearly Profit, Operating, Gross MarginsICCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

1

2. Health

2.1 Basic Checks

ICCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ICCM has more shares outstanding
ICCM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ICCM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ICCM Yearly Shares OutstandingICCM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ICCM Yearly Total Debt VS Total AssetsICCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

ICCM has an Altman-Z score of -13.92. This is a bad value and indicates that ICCM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -13.92, ICCM is not doing good in the industry: 82.20% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.70 indicates that ICCM is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.70, ICCM is not doing good in the industry: 70.68% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.7
Debt/FCF N/A
Altman-Z -13.92
ROIC/WACCN/A
WACC8.82%
ICCM Yearly LT Debt VS Equity VS FCFICCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 1.18 indicates that ICCM should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.18, ICCM is doing worse than 82.72% of the companies in the same industry.
ICCM has a Quick Ratio of 1.18. This is a bad value and indicates that ICCM is not financially healthy enough and could expect problems in meeting its short term obligations.
ICCM's Quick ratio of 0.88 is on the low side compared to the rest of the industry. ICCM is outperformed by 82.20% of its industry peers.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 0.88
ICCM Yearly Current Assets VS Current LiabilitesICCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.11% over the past year.
ICCM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.46%.
The Revenue has been growing by 15.37% on average over the past years. This is quite good.
EPS 1Y (TTM)4.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-16.46%
Revenue growth 3Y-7.36%
Revenue growth 5Y15.37%
Sales Q2Q%-48.07%

3.2 Future

Based on estimates for the next years, ICCM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.59% on average per year.
ICCM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 90.27% yearly.
EPS Next Y29.73%
EPS Next 2Y17.81%
EPS Next 3Y18.81%
EPS Next 5Y23.59%
Revenue Next Year-3.72%
Revenue Next 2Y87.76%
Revenue Next 3Y104.63%
Revenue Next 5Y90.27%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ICCM Yearly Revenue VS EstimatesICCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M 100M
ICCM Yearly EPS VS EstimatesICCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.2 -0.2 0.4 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ICCM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ICCM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICCM Price Earnings VS Forward Price EarningsICCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICCM Per share dataICCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

ICCM's earnings are expected to grow with 18.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.81%
EPS Next 3Y18.81%

More info and screens

0

5. Dividend

5.1 Amount

ICCM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICECURE MEDICAL LTD

NASDAQ:ICCM (9/18/2025, 8:00:01 PM)

After market: 1.03 -0.01 (-0.96%)

1.04

+0.02 (+1.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-03 2025-11-03
Inst Owners0.28%
Inst Owner Change78.9%
Ins Owners47.49%
Ins Owner ChangeN/A
Market Cap71.40M
Analysts82.22
Price Target2.64 (153.85%)
Short Float %2.83%
Short Ratio0.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.99%
Min EPS beat(2)9.5%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)6.71%
Min EPS beat(4)-4.58%
Max EPS beat(4)26.47%
EPS beat(8)6
Avg EPS beat(8)7.37%
EPS beat(12)9
Avg EPS beat(12)7.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.77%
Min Revenue beat(2)-22.31%
Max Revenue beat(2)-5.23%
Revenue beat(4)0
Avg Revenue beat(4)-13.9%
Min Revenue beat(4)-22.31%
Max Revenue beat(4)-5.23%
Revenue beat(8)2
Avg Revenue beat(8)-16.14%
Revenue beat(12)2
Avg Revenue beat(12)-16.59%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.95%
PT rev (3m)-13.95%
EPS NQ rev (1m)8.33%
EPS NQ rev (3m)8.33%
EPS NY rev (1m)3.12%
EPS NY rev (3m)13.89%
Revenue NQ rev (1m)-30.09%
Revenue NQ rev (3m)-30.09%
Revenue NY rev (1m)-40.69%
Revenue NY rev (3m)-43.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.62
P/FCF N/A
P/OCF N/A
P/B 24.7
P/tB 24.7
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.04
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -147.13%
ROE -538.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.92%
FCFM N/A
ROA(3y)-89.11%
ROA(5y)-66.89%
ROE(3y)-136.41%
ROE(5y)-102.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.03%
GM growth 5Y4.86%
F-Score3
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.7
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.57%
Cap/Sales 2.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.18
Quick Ratio 0.88
Altman-Z -13.92
F-Score3
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)175.33%
Cap/Depr(5y)260.07%
Cap/Sales(3y)15.28%
Cap/Sales(5y)12.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y29.73%
EPS Next 2Y17.81%
EPS Next 3Y18.81%
EPS Next 5Y23.59%
Revenue 1Y (TTM)-16.46%
Revenue growth 3Y-7.36%
Revenue growth 5Y15.37%
Sales Q2Q%-48.07%
Revenue Next Year-3.72%
Revenue Next 2Y87.76%
Revenue Next 3Y104.63%
Revenue Next 5Y90.27%
EBIT growth 1Y-10.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.41%
OCF growth 3YN/A
OCF growth 5YN/A